Preanalytical variables in the coagulation laboratory

Laboratory Medicine

Volumn 34, Issue 1, 2003, Pages 49-57

  Lawrence, Jeffry B ^a  

^a BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LUPUS ANTICOAGULANT; REAGENT; WARFARIN;

ANALYTICAL ERROR; ANALYTICAL PARAMETERS; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL LABORATORY; DRUG MONITORING; HUMAN; INTERNATIONAL STANDARD UNIT; PARTIAL THROMBOPLASTIN TIME; PATIENT; PHLEBOTOMY; PRACTICE GUIDELINE; PROTHROMBIN TIME; REVIEW; THROMBOCYTE COUNT; TUBE;

EID: 0037268806     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/ER9P-64EB-MCFR-47KY     Document Type: Review

References (42)

1. Plebani M, Carraro P. Mistakes in a stat laboratory: Types and frequency. Clin Chem. 1997;43:1348-1351.
2. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95-104.
3. Emery JD, Leifer DW, Moura GL, et al. Whole blood platelet aggregation predicts in vitro and in vivo primary hemostatic function in the elderly. Arterioscl Thromb Vasc Biol. 1995;15:748-753.
4. Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol. 1998;33:891-896.
5. Lawrence JB, Leifer DW, Moura GL, et al. Sex differences in platelet adherence to subendothelium: Relationship to platelet function tests and hematologic variables. Am J Med Sci. 1995;309:201-207.
6. Campbell NR, Hull RD, Brant R, et al. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-78.
7. Gill JC, Endres Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnsosis of von Willebrand's disease. Blood. 1987;69:1692-1695.
8. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.
9. Mavri A, Guzic-Salobir B, Salobir-Pajnic B, et al. Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease. Blood Coagul Fibrinolysis. 2001;12:359-365.
10. Ceriello A, Bortolotti N, Motz E, et al. Red wine protects diabetic patients from meal-induced oxidative stress and thrombosis activation: A pleasant approach to the prevention of cardiovascular disease in diabetes. Eur J Clin Invest. 2001;31:322-328.
11. Miller GJ, Bauer KA, Cooper JA, et al. Activation of the coagulation pathway in cigarette smokers. Thromb Haemost. 1998;79:549-553.
12. Zhang QH, Das K, Siddiqui S, et al. Effects of acute, moderate ethanol consumption on platelet aggregation in platelet-rich plasma and whole blood. Alcohol Clin Exp Res. 2000;24:528-534.
13. Walsh BW, Kulter LH, Wild RA, et al. The effects of raloxifene HCl on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1551.
14. Kadir RA, Economides DL, Sabin CA, et al. Variations in coagulation factors in women: Effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost. 1999;82:1456-1461.
15. Weiss C, Bierhaus A, Kinscherf R, et al. Tissue factor-dependent pathway is not involved in exercise-induced formation of thrombin and fibrin. J Appl Physiol. 2002;92:211-218.
16. Von Kanel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: A biobehavioral pathway to coronary artery disease? Psychosom Med. 2001;63:531-544.
17. Koepke JA, Rodgers JL, Ollivier MJ. Pre-instrumental variables in coagulation testing. Am J Clin Pathol. 1975;64:591-596.
18. NCCLS. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline - Third Edition. NCCLS document H21-A3. 1998 NCCLS, Wayne, PA.
19. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: Implications for treatment of nonsurgical blood loss. Transfusion. 2001;41:977-983.
20. Reneke J, Etzell J, Leslie S, et al. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998;109:754-757.
21. NCCLS. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture: Approved Standard - Fourth Edition. NCCLS document H3-A4. 1998 NCCLS, Wayne, PA.
22. Adcock DM, Kressin DC, Marlar RA. Are discard tubes necessary in coagulation studies? Lab Med. 1997;28:530-533.
23. Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing. Dependence on citrate concentration. Am J Clin Pathol. 1998;109:595-599.
24. Palmer RN, Gralnick HR. Inhibition of cold-promoted activation of the prothrombin time: Studies of new siliconized borosilicate collection tubes in normals and patients receiving warfarin. Am J Clin Pathol. 1985;83:492-494.
25. Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coag Fibrinolysis. 1998;9:463-470.
26. Cummings J. Evacuated tubes for monitoring heparin treatment. Thromb Haemost. 1981;34:939-940.
27. Adcock D, Kressin D, Marlar R. Effect of 3.2% vs. 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997;107:105-110.
28. Vogler EA, Graper JC, Harper GR, et al. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res. 1995;29:1005-1016.
29. Hunt BJ, Parratt R, Cable M, et al. Activation of coagulation and platelets is affected by the hydrophobicity of artificial surfaces. Blood Coagul Fibrinolysis. 1997;8:223-231.
30. Polack B, Barro C, Pernod G, et al. Impact of the blood collection tube on the activation of coagulation. Thromb Haemost. 1997;77:217-218.
31. van den Besselaar AMHP, Meeuwisse J, Wineveen E, et al. Effect of blood collection tubes on thromboplastin calibration. Thromb Haemost. 1998;79:1062-1063.
32. D'Angelo G, Villa C. Measurement of prothrombin time in patients on oral anticoagulant therapy: Effect of two different evacuated tubes. Haematologica 1999;84:656-672.
33. van den Besselaar AMHP, Bertina RM, van der Meer, et al. Different sensitivities of various thromboplastins to two blood collection systems for monitoring oral anticoagulant therapy. Thromb Haemost. 1999;82:153-154.
34. Biron-Adreani C, Mallol C, Seguret F, et al. Plastic versus siliconized glass tubes: Evaluation in current laboratory practice. Thromb Haemost. 2000;83:800-801.
35. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol. 1996;27:1349-1355.
36. Hirsh J, Hoak J. Management of deep venous thrombosis and pulmonary embolism: A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996;93:2212-2245.
37. Mody M, Lazarus AH, Semple JW, et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med. 1999;9:147-154.
38. Duncan EM, Casey CR, Duncan BM, et al. Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalized ratio and the international sensitivity index of thromboplastin. Thromb Haemost. 1994;72:84-88.
39. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation. 1994;89:1449-1468.
40. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
41. Siegel JE, Bernard DW, Swami VK, et al. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes. Am J Clin Pathol. 1998;110:184-187.
42. Berger RL, Hsu JC. Bioequivalence trials, intersection-union tests, and equivalence confidence sets. Statistical Science. 1996;11:282-302.